Clinical trials: sponsored by Kite, A Gilead Company
Multiple Myeloma
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
- Trial name
- iMMagine-1 (NCT05396885)
- Testing
- anitocabtagene-autoleucel
- Where
- 18 sites in United States
- Volunteers
- 136 people
- Sponsor
- Kite, A Gilead Company
Relapsed and Refractory Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
- Trial name
- NCT04155749
- Testing
- anitocabtagene-autoleucel
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kite, A Gilead Company
Relapsed or Refractory Large B-cell Lymphoma
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
- Trial name
- ZUMA-24 (NCT05459571)
- Testing
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 16 sites in United States
- Volunteers
- 35 people
- Sponsor
- Kite, A Gilead Company
Follicular Lymphoma, Marginal Zone Lymphoma
A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
The goal of this study is to assess whether axicabtagene ciloleucel improves the clinical outcome in participants with relapsed or refractory indolent non-Hodgkin lymphoma (r/r) iNHL.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
- Trial name
- ZUMA-5 (NCT03105336)
- Testing
- Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 19 sites in United States, France
- Volunteers
- 159 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell…
- Trial name
- ZUMA-7 (NCT03391466)
- Testing
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Follicular Lymphoma
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma
- Trial name
- ZUMA-22 (NCT05371093)
- Testing
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine
- Where
- 52 sites in United States, France and 5 more
- Volunteers
- 231 people
- Sponsor
- Kite, A Gilead Company
Acute Myeloid Leukemia
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
- Trial name
- NCT04789408
- Testing
- Cyclophosphamide, Fludarabine, KITE-222
- Where
- 9 sites in United States, France
- Volunteers
- 15 people
- Sponsor
- Kite, A Gilead Company
B-cell Lymphoma
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
- Trial name
- ZUMA-12 (NCT03761056)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 42 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL).
- Trial name
- ZUMA-3 (NCT02614066)
- Testing
- brexucabtagene autoleucel, Cyclophosphamide, Fludarabine
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 125 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Large B-cell Lymphoma
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
The primary objectives of this study are: Phase 1: To evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and to identify the most appropriate dose and timing of utomilumab to carry forward into Phase 2…
- Trial name
- ZUMA-11 (NCT03704298)
- Testing
- Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
This study will be separated into 3 distinct phases designated as the Phase 1 study, Phase 2 pivotal study (Cohort 1 and Cohort 2), and Phase 2 safety management study (Cohort 3 and Cohort 4, Cohort 5 and Cohort 6).
- Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL)
- Trial name
- ZUMA-1 (NCT02348216)
- Testing
- Axicabtagene Ciloleucel, Fludarabine, Cyclophosphamide
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 307 people
- Sponsor
- Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma
Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens. The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete…
- Trial name
- ZUMA-6 (NCT02926833)
- Testing
- KTE-C19, Atezolizumab, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Large B-cell Lymphoma
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
The primary objectives of this study are: Phase 1: To evaluate the safety of sequenced therapy with lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B-cell lymphoma and identify the most…
- Trial name
- ZUMA-19 (NCT04314843)
- Testing
- Cyclophosphamide, Fludarabine, Lenzilumab
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Kite, A Gilead Company
Refractory Large B-cell Lymphoma
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma
The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell…
- Trial name
- ZUMA-14 (NCT04002401)
- Testing
- Axicabtagene Ciloleucel, Rituximab, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 27 people
- Sponsor
- Kite, A Gilead Company
Non-Small Cell Lung Cancer, Ovarian Cancer
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express…
- Conditions
- Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04025216
- Testing
- CART-TnMUC1, Cyclophosphamide, Fludarabine
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r…
- Trial name
- ZUMA-8 (NCT03624036)
- Testing
- brexucabtagene autoleucel, Fludarabine, Cyclophosphamide
- Where
- 22 sites in United States, Italy
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma
Axicabtagene Ciloleucel Expanded Access Study
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.
- Conditions
- Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma, Relapsed/Refractory Transformed Follicular Lymphoma, Relapsed/Refractory High-Grade B-Cell Lymphoma
- Trial name
- ZUMA-9 (NCT03153462)
- Testing
- Axicabtagene Ciloleucel
- Where
- 15 sites in United States
- Sponsor
- Kite, A Gilead Company
Relapsed/Refractory Multiple Myeloma
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell…
- Trial name
- NCT03318861
- Testing
- KITE-585, Cyclophosphamide, Fludarabine
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- Kite, A Gilead Company
Solid Tumor
Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.
- Trial name
- NCT03139370
- Testing
- KITE-718, Cyclophosphamide, Fludarabine
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Relapse/Refractory Mantle Cell Lymphoma
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
The primary objectives of this study are: Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with relapsed or refractory (r/r) mantle cell lymphoma (MCL) until KTE-X19 is commercially available…
- Trial name
- ZUMA-18 (NCT04162756)
- Testing
- Brexucabtagene Autoleucel (KTE-X19), Fludarabine, Cyclophosphamide
- Where
- 9 sites in United States
- Sponsor
- Kite, A Gilead Company